5q Spinal Muscular Atrophy Therapeutics
1. Evrysdi patent expiration
Treatment: Treatment of spinal muscular atrophy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9969754 | GENENTECH | Compounds for treating spinal muscular atrophy |
May, 2035
(9 years from now) | |
| US12122789 | GENENTECH | Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
Apr, 2041
(15 years from now) | |
| US9586955 | GENENTECH | Compounds for treating spinal muscular atrophy |
Feb, 2033
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350273 | GENENTECH | Treatment Of Sma |
Oct, 2038
(12 years from now) | |
| US11534444 | GENENTECH | Treatment of SMA |
Oct, 2038
(12 years from now) | |
| US11827646 | GENENTECH | Compounds for treating spinal muscular atrophy |
Jan, 2036
(9 years from now) | |
| US11938136 | GENENTECH | Compositions for treating spinal muscular atrophy |
Nov, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| M(M-270) | Oct 03, 2026 |
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 11 February, 2025
Dosage: TABLET; FOR SOLUTION
How can I launch a generic of EVRYSDI before it's drug patent expiration?
More Information on Dosage
EVRYSDI family patents
2. Spinraza patent expiration
Treatment: Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; Treatment of spinal muscular atrophy; Treatment of type iii spinal muscular atrophy; Treatment of infantile-onset spin...
SPINRAZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6166197 | BIOGEN | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec, 2017
(8 years ago) | |
| US7101993 | BIOGEN | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(2 years ago) | |
| US8361977 | BIOGEN | Compositions and methods for modulation of SMN2 splicing |
Dec, 2030
(4 years from now) | |
| US7838657 | BIOGEN | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Jul, 2027
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6210892 | BIOGEN | Alteration of cellular behavior by antisense modulation of mRNA processing |
Oct, 2018
(7 years ago) | |
| US9926559 | BIOGEN | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(7 years from now) | |
| US9717750 | BIOGEN | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(4 years from now) | |
| US8110560 | BIOGEN | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(2 months ago) | |
| US12013403 | BIOGEN | Compositions and methods for detection of SMN protein in a subject and treatment of a subject |
Mar, 2036
(10 years from now) | |
| US10266822 | BIOGEN | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(2 months ago) | |
| US10436802 | BIOGEN | Methods for treating spinal muscular atrophy |
Sep, 2035
(9 years from now) | |
| US8980853 | BIOGEN | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Dosage: SOLUTION
More Information on Dosage
SPINRAZA family patents